Wall Street Today: Nvidia and Chips Pull Back Hard, Market Falls, Dow Holds On
Live Stock: NVIDIA Falling 15%, If It only Takes ~$6M for a Singularity, Why is the Market Paying Trillions
Merck Insiders Sell US$6.4m Of Stock, Possibly Signalling Caution
Express News | Merck Shares Are Trading Higher After the Company Announced WELIREG Has Gained FDA Priority Review
TD Cowen Adjusts Price Target on Merck to $121 From $140
Merck's WELIREG Gains FDA Priority Review for Treating Advanced Pheochromocytoma and Paraganglioma
Express News | Merck & Co Inc - FDA Sets Pdufa Date of May 26, 2025 for Welireg
Express News | FDA Grants Priority Review to Merck’s Application for Welireg® (Belzutifan) for the Treatment of Patients With Advanced Pheochromocytoma and Paraganglioma (Ppgl)
Optimistic Buy Rating for Merck & Co. Driven by Winrevair Projections and Financial Strength
Is Merck & Co., Inc. (MRK) the Best Dow Stocks to Buy Right Now?
Weekly Buzz: Last Short Week of Jan Sees Records, Trump Gives Orders
Wall Street Today: Market Pulls Back After Wild Week
Unusual Options Activity: VFC, PDD and Others Attract Market Bets, VFC V/OI Ratio Reaches 315.8
Live Stock: First Week Down, Market Pulls Back a Hair After Records
Fund Update: DAVENPORT & Co LLC Just Disclosed New Holdings
Merck, Eisai Gastroesophageal Cancer Combo Therapy Meets One Primary Endpoint in Trial
Why Is Billionaire Prem Watsa Bullish on Merck & Co., Inc. (MRK) Now?
Merck, Eisai Update On Phase 3 LEAP-015 Trial; At Interim Analysis, Keytruda Plus Lenvima-based Regimen Showed Statistically Significant Improvement In Progression-free Survival
Express News | Merck & Co Inc - Safety Profile Consistent With Previous Studies
Express News | Merck & Co Inc - Keytruda Plus Lenvima Shows Significant Improvement in Pfs and Orr